EA200100770A1 - Применение агентов, индуцирующих апоптоз, в лечении (ауто)имунных заболеваний - Google Patents

Применение агентов, индуцирующих апоптоз, в лечении (ауто)имунных заболеваний

Info

Publication number
EA200100770A1
EA200100770A1 EA200100770A EA200100770A EA200100770A1 EA 200100770 A1 EA200100770 A1 EA 200100770A1 EA 200100770 A EA200100770 A EA 200100770A EA 200100770 A EA200100770 A EA 200100770A EA 200100770 A1 EA200100770 A1 EA 200100770A1
Authority
EA
Eurasian Patent Office
Prior art keywords
auto
immune diseases
treatment
application
inducing apoptosis
Prior art date
Application number
EA200100770A
Other languages
English (en)
Inventor
Матиу Хубертус Мария Нотеборн
Александра Мария Питерсен
Original Assignee
Леадд Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Леадд Б.В. filed Critical Леадд Б.В.
Publication of EA200100770A1 publication Critical patent/EA200100770A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Изобретение относится к терапиям (ауто)иммунных заболеваний. Синтез или присутствие апоптической активности в клетках, вызывающих (ауто)иммунные заболевания или связанных с этими заболеваниями, таких как синовиоциты при ревматоидном артрите, приводят к индукции апоптоза. Изобретение также относится к ген-доставляющим носителям, которые представляют собой молекулы, кодирующие синтез апоптоз-индуцирующих белков с апоптин-подобной активностью.Отчет о международном поиске был опубликован 2000.09.28.
EA200100770A 1999-01-11 2000-01-10 Применение агентов, индуцирующих апоптоз, в лечении (ауто)имунных заболеваний EA200100770A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99200056 1999-01-11
PCT/NL2000/000013 WO2000041497A2 (en) 1999-01-11 2000-01-10 Use of apoptosis inducing agents in the treatment of (auto)immune diseases

Publications (1)

Publication Number Publication Date
EA200100770A1 true EA200100770A1 (ru) 2002-02-28

Family

ID=8239795

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100770A EA200100770A1 (ru) 1999-01-11 2000-01-10 Применение агентов, индуцирующих апоптоз, в лечении (ауто)имунных заболеваний

Country Status (18)

Country Link
US (1) US20050271624A1 (ru)
EP (1) EP1143994B1 (ru)
JP (1) JP2003500336A (ru)
AT (1) ATE244014T1 (ru)
AU (1) AU3083500A (ru)
CA (1) CA2359392A1 (ru)
DE (1) DE60003632T2 (ru)
DK (1) DK1143994T3 (ru)
EA (1) EA200100770A1 (ru)
ES (1) ES2202039T3 (ru)
HU (1) HUP0200552A2 (ru)
IL (2) IL144228A0 (ru)
MX (1) MXPA01006998A (ru)
NO (1) NO20013397L (ru)
PT (1) PT1143994E (ru)
TR (1) TR200102713T2 (ru)
WO (1) WO2000041497A2 (ru)
ZA (1) ZA200105632B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002246455A1 (en) * 2001-03-30 2002-10-15 Leadd B.V. Fusion proteins for specific treatment of cancer and auto-immune diseases
JP4584573B2 (ja) * 2001-05-25 2010-11-24 ナイモックス コーポレーション 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド
BR0211199A (pt) * 2001-07-19 2004-10-26 Nymox Corp Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
US7317077B2 (en) * 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5981502A (en) * 1990-09-12 1999-11-09 Leadd B.V. Methods and compositions for inducing apoptosis in tumor cells
EP0878546A1 (en) * 1997-04-15 1998-11-18 Leadd B.V. A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or apoptin
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
AU718422B2 (en) * 1995-06-07 2000-04-13 Leadd B.V. Methods and uses for apoptin
WO1997029201A2 (de) * 1996-02-07 1997-08-14 Max-Delbrück-Centrum für Molekulare Medizin Retroviraler vektor für den gentransfer eines il6-antagonisten in humane hämatopoetische stammzellen
BR9807622A (pt) * 1997-02-28 2000-02-15 Boehringer Ingelheim Pharma Apoptose auto-regulada de células inflamatórias por terapia de gene
AU736287B2 (en) * 1997-03-21 2001-07-26 Sankyo Company Limited Humanized anti-human Fas antibody
JPH10324699A (ja) * 1997-03-21 1998-12-08 Sankyo Co Ltd 抗ヒトＦａｓヒト化抗体

Also Published As

Publication number Publication date
PT1143994E (pt) 2003-11-28
ZA200105632B (en) 2002-10-09
NO20013397L (no) 2001-09-11
DE60003632T2 (de) 2004-04-15
DE60003632D1 (de) 2003-08-07
CA2359392A1 (en) 2000-07-20
WO2000041497A2 (en) 2000-07-20
JP2003500336A (ja) 2003-01-07
US20050271624A1 (en) 2005-12-08
MXPA01006998A (es) 2002-05-06
ES2202039T3 (es) 2004-04-01
TR200102713T2 (tr) 2002-05-21
HUP0200552A2 (en) 2002-06-29
DK1143994T3 (da) 2003-10-20
AU3083500A (en) 2000-08-01
EP1143994B1 (en) 2003-07-02
IL144228A (en) 2009-06-15
ATE244014T1 (de) 2003-07-15
IL144228A0 (en) 2002-05-23
EP1143994A2 (en) 2001-10-17
NO20013397D0 (no) 2001-07-09
WO2000041497A3 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
DK0721449T3 (da) Inhibitorer af beta-amyloidproteinproduktion
TR200001023T2 (tr) Alfa-aril-N-Alkilnitronlar ve onları içeren farmasötik kompozisyonlar.
DK0690720T3 (da) Terapeutiske anvendelser af baktericide/permeabilitetsforøgende proteinprodukter
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
DE69516847T2 (de) Chlorpyrimidine als zwischenprodukte
BR9907995A (pt) Métodos imunológicos para modular miostatina em sujeitos vertebrados
DE60032486D1 (de) Prion protein peptide und deren verwendung
DE60136054D1 (de) Apoptose-induzierendes polypeptid
ATE193839T1 (de) Reinigung von proteinen
DE69128543D1 (de) Monoklonale antikörper der maus
FI961083A (fi) Rekombinentti-IL4-vasta-aineita, jotka ovat käyttökelpoisia IL-4-välitteisten häiriötilojen hoidossa
ATE483806T1 (de) Polynukleotide, welche für mitglieder der humanen b lymphozyten-aktivierendes antigen familie kodieren, und von diesen kodierte polypeptide
DE69425820T2 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
DK1220852T3 (da) Substituerede diazepaner
EA200100770A1 (ru) Применение агентов, индуцирующих апоптоз, в лечении (ауто)имунных заболеваний
TR199800517A2 (xx) H�manize anti-h�men fas antikor.
ATE395935T1 (de) An der oberfläche von karzinomzellen lokalisiertes colligin/hsp47
EP1475441A3 (fr) Acides nucléiques et polypeptides spécifiques des souches pathogènes du genre Neisseria
NO20020329D0 (no) Antitumor antistoffer, proteiner og anvendelser derav
DK1377667T3 (da) Fusionsproteiner til specifik behandling af cancer og autoimmunsygdomme
BR0108187A (pt) Moléculas trade e usos relacionados com as mesmas
DE69933690D1 (de) Apoptosis induzierender faktor
DK0858465T3 (da) Protein med antitumorvirkning.